S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.01 (+0.92%)
AAPL   116.59 (+0.48%)
MSFT   215.23 (+0.64%)
FB   277.81 (+0.81%)
GOOGL   1,787.02 (+1.30%)
AMZN   3,195.34 (+0.32%)
TSLA   585.76 (+2.05%)
NVDA   530.45 (+0.20%)
BABA   276.48 (-0.45%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.19 (+0.55%)
T   29.03 (+0.14%)
NIO   54.00 (+0.58%)
F   9.09 (+0.11%)
ACB   10.47 (+20.21%)
NFLX   491.36 (+1.31%)
GILD   60.03 (+0.89%)
BA   216.50 (-0.51%)
DIS   147.13 (-1.31%)
Log in
NASDAQ:REPL

Replimune Group Stock Forecast, Price & News

$51.83
+1.81 (+3.62 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$50.00
Now: $51.83
$53.00
50-Day Range
$24.07
MA: $42.59
$50.02
52-Week Range
$8.58
Now: $51.83
$54.85
Volume101,850 shs
Average Volume294,073 shs
Market Capitalization$2.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.23
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More
Replimune Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPL
CUSIPN/A
CIKN/A
Phone781-222-9600
Employees122

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-52,630,000.00

Miscellaneous

Market Cap$2.38 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableNot Optionable
$51.83
+1.81 (+3.62 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REPL News and Ratings via Email

Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Replimune Group (NASDAQ:REPL) Frequently Asked Questions

How has Replimune Group's stock price been impacted by COVID-19 (Coronavirus)?

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPL shares have increased by 334.5% and is now trading at $51.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Replimune Group?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Replimune Group
.

What stocks does MarketBeat like better than Replimune Group?

Wall Street analysts have given Replimune Group a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Replimune Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Replimune Group
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its earnings results on Thursday, November, 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.03.
View Replimune Group's earnings history
.

What price target have analysts set for REPL?

9 Wall Street analysts have issued 12 month target prices for Replimune Group's stock. Their forecasts range from $44.00 to $67.00. On average, they expect Replimune Group's share price to reach $54.25 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price.
View analysts' price targets for Replimune Group
.

Are investors shorting Replimune Group?

Replimune Group saw a increase in short interest in October. As of October 30th, there was short interest totaling 1,020,000 shares, an increase of 29.8% from the October 15th total of 785,700 shares. Based on an average trading volume of 611,600 shares, the short-interest ratio is presently 1.7 days. Currently, 4.0% of the company's shares are sold short.
View Replimune Group's Short Interest
.

Who are some of Replimune Group's key competitors?

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), (BTUUQ) (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

Who are Replimune Group's key executives?

Replimune Group's management team includes the following people:
  • Mr. Philip Astley-Sparke, CEO & Director (Age 49, Pay $613.95k)
  • Dr. Robert Coffin, Founder, Pres, Chief R&D Officer and Director (Age 55, Pay $725.79k)
  • Ms. Jean M. Franchi, Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer (Age 54, Pay $470.87k)
  • Dr. Pamela Esposito Ph.D., Chief Bus. Officer (Age 46, Pay $464.63k)
  • Dr. Colin Love, Chief Operating Officer (Age 62)
  • Dr. Andrea Pirzkall M.D., Chief Medical Officer (Age 50)

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.75%), Victory Capital Management Inc. (2.96%), Point72 Asset Management L.P. (2.15%), Emerald Advisers LLC (2.21%), Emerald Mutual Fund Advisers Trust (2.05%) and Corriente Advisors LLC (1.27%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends for Replimune Group
.

Which major investors are selling Replimune Group stock?

REPL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, and Wells Fargo & Company MN. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Pamela Esposito, and Robert Coffin.
View insider buying and selling activity for Replimune Group
.

Which major investors are buying Replimune Group stock?

REPL stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., Charles Schwab Investment Management Inc., Caas Capital Management LP, Victory Capital Management Inc., Letko Brosseau & Associates Inc., Emerald Advisers LLC, and JPMorgan Chase & Co.. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv LP Omega, and Jason P Rhodes.
View insider buying and selling activity for Replimune Group
.

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $51.83.

How big of a company is Replimune Group?

Replimune Group has a market capitalization of $2.38 billion. The company earns $-52,630,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Replimune Group employs 122 workers across the globe.

What is Replimune Group's official website?

The official website for Replimune Group is www.replimune.com.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.